Pharmacogenomics and Effective Treatment With Clopidogrel

Can Pharmacogenomic Testing Improve Response and Avoid Adverse Effects With Clopidogrel Therapy? A Biospecimen Bank for Genetic and Genomic Investigation of Clopidogrel.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01611545

Enrollment

130

Registered

2012-06-05

Start date

2012-06-30

Completion date

2015-01-31

Last updated

2015-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pharmacogenomics and Cardiovascular Events

Keywords

Pharmacogenomics, Pharmacogenetics, Clopidogrel, Plavix

Brief summary

The aim of this biospecimen repository is to evaluate an individual's genotype, identify the variances, and understand how they relate to treatment with clopidogrel.

Detailed description

The objective of this project is to distinguish genetic profiles that will assist a practitioner in determining the right dose or alternate medication for the patient. In partnership with the genetics team of the Avera Institute for Human Genetics and physicians with the Avera Heart Hospital of South Dakota and North Central Heart Institute, the research team will perform genetic analysis to identify genetic variances.

Interventions

GENETICPharmacogenomics

Utilizing pharmacogenomics to determine the most effective treatment

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Currently taking or prescribed Clopidogrel or under consideration * Acute/interventionPatients of the Avera Heart Hospital * Cardiology clinic patients with the Avera Heart Hospital and North Central Heart Institute

Exclusion criteria

* Unable to provide informed consent

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026